Contrast-enhanced ultrasonography–CT/MRI fusion guidance for percutaneous ablation of inconspicuous, small liver tumors: improving feasibility and therapeutic outcome

医学 射频消融术 放射科 经皮 烧蚀 超声造影 肝肿瘤 肝细胞癌 超声波 超声科 内科学
作者
Yuna Lee,Jeong Hee Yoon,Seung-Wan Han,Ijin Joo,Jeong Min Lee
出处
期刊:Cancer Imaging [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40644-023-00650-y
摘要

Percutaneous radiofrequency ablation (RFA) is pivotal for treating small malignant liver tumors, but tumors often remain inconspicuous on B-mode ultrasound (US). This study evaluates the potential of CEUS-CT/MRI fusion imaging (FI) to improve tumor visibility and the associated RFA outcomes for small (≤ 3 cm) malignant liver tumors that were inconspicuous on US.Between January 2019 and April 2021, a prospective study enrolled 248 patients with liver malignancies (≤ 3 cm) that were poorly visible on B-mode US. Tumor visibility and ablation feasibility were assessed using B-mode US, US-CT/MRI FI, and CEUS-CT/MRI FI, and graded on a 4-point scale. CEUS was employed post-registration of US and CT/MRI images, utilizing either SonoVue or Sonazoid. Comparisons between US-based and CEUS-based fusion visibility and feasibility scores were undertaken using the Friedman test. Moreover, rates of technical success, technique efficacy, local tumor progression (LTP), and major complications were assessed.The cohort included 223 hepatocellular carcinomas (HCCs) (89.9%) and 23 metastases (9.3%), with an average tumor size of 1.6 cm. CEUS-CT/MRI FI demonstrated a significant advantage in tumor visibility (3.4 ± 0.7 vs. 1.9 ± 0.6, P < 0.001) and technical feasibility (3.6 ± 0.6 vs. 2.9 ± 0.8, P < 0.001) compared to US-FI. In 85.5% of patients, CEUS addition to US-FI ameliorated tumor visibility. Technical success was achieved in 99.6% of cases. No severe complications were reported. One and two-year post CEUS-CT/MRI FI-guided RFA estimates for LTP were 9.3% and 10.9%, respectively.CEUS-CT/MRI FI significantly improves the visualization of tumors not discernible on B-mode US, thus augmenting percutaneous RFA success and delivering improved therapeutic outcomes.ClinicalTrials.gov, NCT05445973. Registered 17 June 2022 - Retrospectively registered, http://clinicaltrials.gov/study/NCT05445973?id=NCT05445973&rank=1 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bioinfo_sc完成签到,获得积分10
1秒前
牛油果完成签到,获得积分10
1秒前
沙司利益完成签到 ,获得积分10
2秒前
2秒前
阔达又夏完成签到 ,获得积分10
3秒前
4秒前
打打应助dijla采纳,获得10
6秒前
6秒前
一坨耙耙发布了新的文献求助10
7秒前
年轻的冷雁完成签到,获得积分10
8秒前
糖糖完成签到 ,获得积分20
8秒前
9秒前
元气完成签到,获得积分10
9秒前
ycc发布了新的文献求助10
10秒前
田様应助zzxc采纳,获得10
11秒前
haihai完成签到 ,获得积分10
11秒前
周才完成签到,获得积分10
11秒前
freemaisui完成签到,获得积分10
12秒前
万能图书馆应助吴雨采纳,获得10
12秒前
孙志英完成签到,获得积分10
13秒前
Chan0427发布了新的文献求助10
13秒前
Q1n完成签到,获得积分10
14秒前
科研助理795应助LiBang采纳,获得10
15秒前
16秒前
ycc完成签到,获得积分10
16秒前
852应助xzheng采纳,获得10
16秒前
Nsdy完成签到 ,获得积分10
17秒前
蕲艾比比谁完成签到,获得积分10
17秒前
17秒前
111发布了新的文献求助10
19秒前
优雅土豆完成签到,获得积分10
20秒前
轩轩发布了新的文献求助10
20秒前
20秒前
20秒前
瑞恩发布了新的文献求助10
20秒前
科目三应助tao采纳,获得10
20秒前
丘比特应助Terry采纳,获得10
21秒前
稞小弟完成签到,获得积分10
22秒前
CipherSage应助Chan0427采纳,获得10
25秒前
斯文败类应助不倒翁37采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Principles of town planning: translating concepts to applications 1000
Navigating Normative Orders. Interdisciplinary Perspectives 800
1 Peter and Christ's Descent to the Dead in Its Early Christian Reception 700
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7740758
求助须知:如何正确求助?哪些是违规求助? 9289329
关于积分的说明 20195155
捐赠科研通 7318894
什么是DOI,文献DOI怎么找? 3306525
关于科研通互助平台的介绍 2458797
邀请新用户注册赠送积分活动 2316767